title: [Microalbuminuria is an early marker for increased morbidity and mortality].
abstract: Recent studies have shown the beneficial effects of a blockade of the renin-angiotensin system (RAS) not only for blood pressure reduction but also end organ protection. One of the markers that is closely correlated with the increased cardiovascular risk is microalbuminuria. A common mediator for the development of both, microalbuminuria and end organ damage seems to be Angiotensin II, the blockade of which apparently reduces microalbuminuria as well as end organ damage. Therefore we had a closer look into pathophysiology of microalbuminuria and the relevance for end organ damage and discuss current medical strategies to alleviate these diseases.
authors.affiliation: Institut für klinische Psychologie und Psychotherapie, TU Dresden.
authors.forename: P
authors.initials: P
authors.lastname: Bramlage
authors.forename: H U
authors.initials: HU
authors.lastname: Wittchen
authors.forename: D
authors.initials: D
authors.lastname: Pittrow
authors.forename: R
authors.initials: R
authors.lastname: Dikow
authors.forename: W
authors.initials: W
authors.lastname: Kirch
authors.forename: H
authors.initials: H
authors.lastname: Lehnert
authors.forename: E
authors.initials: E
authors.lastname: Ritz
mesh_terms: D000419:Albuminuria / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000401:mortality; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000209:etiology / Q000401:mortality; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D015201:Meta-Analysis as Topic; D015995:Prevalence; D011507:Proteinuria / Q000209:etiology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000401:mortality
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D000804:Angiotensin II; D019808:Losartan